Clinical Trials Logo

Clinical Trial Summary

The aim of the joint project PROVID is to contribute to better outcome prediction for COVID-19 patients, to better clinical management, and to the development of new therapies. To this end, the investigators will collect detailed data on the course of COVID-19 patients and deeply characterize them at the molecular level. The investigators also aim to identify compounds with the potential to improve outcome. The PROVID-PROGRESS study is being carried out as a prospective, longitudinal, multicenter observational study (case cohort study) with material asservation for genomic, transcriptomic and proteomic analyzes on adult patients with COVID-19.


Clinical Trial Description

With COVID-19, severe lung damage can be associated with relative well-being. In the course of disease (several days), sudden lung failure may occur. While the lung initially shows a relatively high compliance after intubation, lung function deteriorates rapidly to severe ARDS in most patients. After intubation, patients require mechanical ventilation over a relatively long period of time (17 days on average). To improve the clinical management of COVID-19 and its complications, there is an urgent need for clinical (e.g., scores) and molecular (e.g., biomarkers) predictors of COVID-19 progression and for new therapeutic targets. Advanced age and comorbidities have been identified as risk factors for fatal disease progression. After study inclusion, comprehensive baseline documentation of anamnestic, clinical and laboratory data is collected on the same day if possible. In addition, all parameters are collected that may be necessary to assess the severity of a COVID-19 disease (e.g. SOFA, PSI, C (U) RB-65, ATS minor criteria). Furthermore, data is collected which, according to the current state of knowledge, may be suitable for an assessment of the prognosis of the COVID-19 disease. In particular, questions are asked about known infection risks (living environment of the patient, lifestyle, previous illnesses, immune competence), the history of symptoms and tests relating to COVID-19, preexisting medication, the familial risk of infection as well as ethnicity. On the day of inclusion (day 0) and on study visit days 1-6 and 13 - or for discharge if this occurs before day 6 or day 13 after inclusion - routine laboratory values, score-relevant data, concomitant medication and microbiological findings are documented. On discharge of the patient, additional information about his whereabouts is collected. If the patient dies, the date and cause of death are documented. On days 28, 180 and 360 after inclusion in the study, a follow-up survey takes place with particular attention to the living conditions and quality of life of the patient (EuroQol health questionnaire EQ-5D-3L), to health-related events such as stroke or heart attack and to the vital status. If the patient cannot be reached for the follow-up questionnaires, the including study center will attempt to determine the current contact details or vital status from relatives, the family doctor or, if necessary, from data from the residents' registration offices or other state registers, provided that consent is given. On study visit days 0, 1-3, 6 and 13, 4 blood samples each (P100 EDTA plasma, citrate plasma, serum and PAXgene RNA) are taken. A DNA sample (EDTA whole blood) is taken once and at any time. A nasopharynx swab is obtained on days 0, 3 and 6. If possible, sputum is obtained for inclusion and on visit day 6. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04977934
Study type Observational
Source Charite University, Berlin, Germany
Contact
Status Active, not recruiting
Phase
Start date January 20, 2021
Completion date June 30, 2023

See also
  Status Clinical Trial Phase
Suspended NCT04901676 - Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia Phase 3
Not yet recruiting NCT04534478 - Oral Prednisone Regimens to Optimize the Therapeutic Strategy in Patients With Organizing Pneumonia Post-COVID-19 Phase 4
Active, not recruiting NCT05002517 - Randomized, Unicentric, Open, Controlled Clinical Trial, in Phase Iii, to Demonstrate the Effectiveness of Tocilizumab Phase 3
Completed NCT05008393 - Efficacy of PJS-539 for Adult Patients With COVID-19. Phase 2
Completed NCT04569877 - GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia Phase 2
Not yet recruiting NCT05286255 - Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias Phase 1
Not yet recruiting NCT05890573 - Efficacy of Bailing Capsule on Pulmonary Fibrosis After COVID-19 N/A
Completed NCT05035589 - The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
Recruiting NCT06113432 - CPAP Therapy Through a Helmet or a Full Face Mask in Patients With Acute Hypoxemic Respiratory Failure: Cross-over Study N/A
Recruiting NCT05042063 - Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
Recruiting NCT04615429 - Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19 Phase 2
Completed NCT05047653 - RALE Versus CORADS/CT-Severity Score in COVID-19
Active, not recruiting NCT05047016 - Study to Evaluate the Dynamic Consent Model Based on the Blockchain-based Clinical Trial Platform METORY N/A
Active, not recruiting NCT05033847 - Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above Phase 2
Recruiting NCT06113757 - Investigation of Efficacy and Safety of Electrical Signal Therapy Provided by Dr Biolyse® Device in COVID-19 Disease N/A
Completed NCT05504655 - N-Acetylcysteine as an Adjuvant Therapy in Critically Ill COVID-19 Patients:
Active, not recruiting NCT05035524 - A Randomized Controlled Trial to Investigate The Role of Adjuvant Inhalable Sodium Bicarbonate Solution 8.4% in Treatment of COVID-19 N/A
Completed NCT05065879 - Evaluation of Immunogenicity and Safety of COVID-19 Vaccine (Produced in Beijing) in Patients With Hypertension and/or Diabetes Phase 4
Withdrawn NCT04390217 - LB1148 for Pulmonary Dysfunction Associated With COVID-19 Pneumonia Phase 2
Withdrawn NCT04460105 - Lanadelumab in Participants Hospitalized With COVID-19 Pneumonia Phase 1